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In in vitro studies class-I PI3Ks (phosphoinositide 3-kinases),
class-II PI3Ks and mTOR (mammalian target of rapamycin)
have all been described as having roles in the regulation of
glucose metabolism. The relative role each plays in the normal
signalling processes regulating glucose metabolism in vivo is less
clear. Knockout and knockin mouse models have provided some
evidence that the class-I PI3K isoforms p110α, p110β,a n dt o
a lesser extent p110γ, are necessary for processes regulating
glucose metabolism and appetite. However, in these models the
PI3K activity is chronically reduced. Therefore we analysed
the effects of acutely inhibiting PI3K isoforms alone, or PI3K and
mTOR, on glucose metabolism and food intake. In the present
study impairments in glucose tolerance, insulin tolerance and
increased hepatic glucose output were observed in mice treated
with the pan-PI3K/mTOR inhibitors PI-103 and NVP-BEZ235.
The ﬁnding that ZSTK474 has similar effects indicates that these
effects are due to inhibition of PI3K rather than mTOR. The
p110α-selective inhibitors PIK75 and A66 also induced these
phenotypes, but inhibitors of p110β, p110δ or p110γ induced
only minor effects. These drugs caused no signiﬁcant effects on
BMR (basal metabolic rate), O2 consumption or water intake,
but BEZ235, PI-103 and PIK75 did cause a small reduction in
food consumption. Surprisingly, pan-PI3K inhibitors or p110α
inhibitors caused reductions in animal movement, although the
cause of this is not clear. Taken together these studies provide
pharmacological evidence to support a pre-eminent role for the
p110α isoform of PI3K in pathways acutely regulating glucose
metabolism.
Key words: glucose metabolism, insulin, mammalian target
of rapamycin (mTOR), phosphoinositide 3-kinase (PI3K),
phosphoinositide 3-kinase catalytic α polypeptide (PIK3CA).
INTRODUCTION
PI3Ks(phosphoinositide3-kinases)areafamilyofeightenzymes
that are capable of phosphorylating the D3 position of the inositol
head group of phosphoinositides. Although all of these enzymes
share a high degree of sequence similarity in the kinase domain,
there are signiﬁcant differences in other domains, and so the
PI3Ks have been divided into three classes based on structural
similarities [1]. The catalytic domain of the PI3K family also
shares a high degree of homology with a family of ﬁve serine
kinasesthatarereferredtoasthePIKKs(phosphoinositidekinase-
related kinases) [2]. This family includes mTOR (mammalian
targetofrapamycin)andATM(ataxiatelangiectasiamutated)[2].
There is a signiﬁcant body of evidence to indicate that various
forms of PI3K play roles in the regulation of glucose metabolism.
Class-II PI3Ks are activated by insulin and have also been
implicated in mediating insulin-induced increases in glucose
uptake[3,4].Theclass-IIIPI3Kisnotregulateddirectlybyinsulin
levels, but is regulated by changes in cellular glucose levels [5].
Of the PIKKs, mTOR [6,7] and ATM [8] have been implicated in
regulating pathways involved in glucose metabolism. The class-
IBPI3Ksmayplayaroleinregulatinginsulinsecretioninvitro[9]
andinvivo[10].However,theroleofclass-IAPI3Ksinmediating
theeffectsofinsulinonglucosemetabolismhasbeeninvestigated
most extensively [11]. A number of approaches have been used
to deﬁne the role of speciﬁc isoforms of class-IA PI3K in the
regulation of glucose metabolism. Overexpression of p110α or
p110β issufﬁcienttoinduceGLUT-4(glucosetransportertype4)
translocation and glucose uptake in vitro [12–16]. However, high-
level expression of PI3Ks does not prove that a particular PI3K
isoform is involved, as forced overexpression of p110 causes not
onlylargeincreasesinPtdIns(3,4,5)P3,butalsointheotherD3in-
ositides,soitispossiblethattheeffectsseenareduetotheincrease
in PtdIns3P, PtdIns(3,4)P2 and PtdIns(3,5)P2 [17]. Global gene
KOs(knockouts)ofp110α andaKI(knockin)thatcreatesakinase
dead allele of p110α are embryonically lethal, and data on insulin
actionhaveonlybeenobtainedfromstudiesofheterozygousmice
[18] or tissue-speciﬁc PI3K KO models [19,20]. These studies
have provided evidence for impairments in glucose metabolism
when levels of p110α are chronically reduced. KI mice have also
been created in which the kinase activity of p110β is ablated and
micehomozygousforthismutationhaveminordefectsinglucose
metabolism, implying a role for the catalytic activity of p110β
in pathways regulating glucose metabolism [20,21]. However,
long-term gene knockdown can cause developmental problems in
key glucoregulatory tissues that could contribute to the defects
in glucose metabolism, and the results of studies with seemingly
similar PI3K KO models do not always produce similar effects
on glucose metabolism [19].
Pharmacological inhibitors offer a more direct means of
studying the role of the catalytic functions of the PI3K enzymes
[22]. A wide range of small molecule inhibitors targeting class-
I PI3K isoforms and mTOR have been developed [2,23,24]. A
number of these are selective for particular class-I PI3K isoforms
and/or mTOR [25–31]. Some of these inhibitors have been used
in a limited range of in vitro studies of insulin action [26,32,33],
but there is very little data available on the in vivo effect of these
inhibitors on glucose metabolism [26].
Abbreviations used: ATM, ataxia telangiectasia mutated; BMR, basal metabolic rate; GTT, glucose tolerance test; ITT, insulin tolerance test; KI, knockin;
KO, knockout; LC-MS/MS, liquid chromatography tandem MS; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; PI3KCA, PI3K
catalytic α polypeptide; PIKK; phosphoinositide kinase-related kinase; PTT, pyruvate tolerance test.
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Figure 1 Acute effect of PI3K inhibitors on insulin tolerance
TheindicatedPI3Kinhibitorswereadministeredintraperitoneally(10mg/kgofbodymass)and1 hlateranimalswereinjectedwithinsulin(0.75units/kgofbodymass).Glucoselevelsinbloodwere
measured in blood samples taken at the indicated time as described in the Experimental section. Results are means+ −S.E.M. (n6). Statistical signiﬁcance was determined by repeated measures
ANOVA (***P <0.001 compared with the vehicle control animals).
In the present study we have investigated the effects of a range
ofinhibitorswithvaryingspeciﬁcityforclass-IPI3Kisoformsand
mTOR on whole-body glucose metabolism in mice. The present
study supports a major role for the p110α isoform of PI3K in
maintaining glucose homoeostasis in vivo. Surprisingly the data
also demonstrate that animals treated with a pan-PI3K inhibitor
or p110α inhibitors display a marked reduction in movement.
EXPERIMENTAL
Animal model
The GTT (glucose tolerance test), ITT (insulin tolerance test)
and PTT (pyruvate tolerance test) studies used male CD1 mice.
Metabolic cage studies used male C57Bl/6 mice that were
mass and percentage of fat matched into groups using the
EchoMRI-100 quantitative magnetic resonance system (Echo
Medical Systems). The light/dark cycle was 12 h in all cases
and all animals were fed on standard laboratory chow (Harland
Teklad). All animal experiments were approved by the Animal
Ethics Committees’ of Auckland University in New Zealand and
the Agency for Science, Technology and Research (A*STAR)
Biomedical Science Institutes in Singapore.
Compounds and reagents
The study used ZSTK474 (pan-PI3K inhibitor) [25], PI-103
(pan-PI3K/mTOR inhibitor) [26], BEZ235 (pan-PI3K inhibitor/
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Figure 2 Acute effect of PI3K inhibitors on hepatic glucose output
The indicated PI3K inhibitors were administered intraperitoneally (10mg/kg of body mass) and 1 h later animals were injected with pyruvate (2g/kg of body mass). Glucose levels in blood were
measured in blood samples taken at the indicated time as described in the Experimental section. Results are means+ −S.E.M. (n6). Statistical signiﬁcance was determined by repeated measures
ANOVA (***P <0.001 compared with the vehicle control animals).
mTOR) [27], PIK75 (p110α inhibitor) [26], A66 (p110α-
selective inhibitor) [28], TGX221 (p110β-selective inhibitor)
[29], IC87114 (p110δ-selective inhibitor) [30] and AS252424
(claimed to be a p110γ-selective inhibitor) [31]. These were
synthesized in-house as described previously [28,32] or obtained
from Symansis. All compounds were greater than 99% pure
by HPLC analysis and NMR data indicated that they were the
correct molecules. Unless otherwise stated, other reagents were
purchased from Sigma Chemicals.
GTT, ITT and PTT
GTTs, ITTs and PTTs, as well as determinations of insulin levels,
were performed as described previously [34], except that male
CD1 mice were used instead of rats. For GTTs and PTTs the
mice were starved overnight and for the ITT food was withdrawn
2 h prior to the start of the experiments. Drugs were dosed
intraperitoneally 1 h after the end of the dark cycle and 1 h prior
to the intraperitoneal dosing with glucose or pyruvate (2 g/kg of
body mass) or insulin (0.75 unit/kg of body mass).
Metabolic cage studies
Oxymax/CLAMS (Columbus Instruments) was used to quantify
oxygenconsumption( ˙ VO2),CO2 production( ˙ VCO2),BMR(basal
metabolic rate), food intake, water intake and animal movement
as described previously [35]. BMR was expressed as a function
of lean body mass as recommended in a previous study [36]. All
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Figure 3 Acute effect of PI3K inhibitors on glucose tolerance
The indicated PI3K inhibitors were administered intraperitoneally (10mg/kg of body mass) and 1h later animals were injected with glucose (2g/kg of body mass). Glucose levels in blood were
measured in blood samples taken at the indicated time as described in the Experimental section. Results are means+ −S.E.M. (n6). Statistical signiﬁcance was determined by repeated measures
ANOVA (*P < 0.05, **P <0.01 and ***P <0.001 compared with the vehicle control animals).
data were normalized to total lean mass using the EchoMRI-100
quantitative magnetic resonance system as described previously
[35]. Animals were acclimatized for 24 h in cages and the data
were collected over the following 24 h.
Analysis of drug levels
Pharmacological kinetics studies were undertaken in fed CD1
male mice (30 g body mass). Animals were administered with the
stated PI3K inhibitors via oral gavage or intraperitoneal injection,
andterminalbloodsampleswerecollectedinEDTAbloodcollec-
tion tubes at 15 min, and 1, 2, 4, 6 and 24 h post-drug exposure.
All drugs were dissolved in DMSO. Blood was centrifuged
(2000 g for 10 min and 4◦C) and plasma isolated for drug
quantiﬁcation. Drug quantiﬁcation was undertaken using LC-
MS/MS (liquid chromatography tandem MS). Brieﬂy, 300 μlo f
100%methanolwasaddedto100 μlofplasma.Thesampleswere
gently mixed and centrifuged (2000 g for 10 min and 4◦C). The
supernatant was removed and 50 μl was added into vials for LC-
MS/MS. The ion-source type was ESI (electrospray ionization)
with the following conditions: spray voltage (5500 V), sheath gas
pressure(50 units),ionsweepgaspressure(0.0 unit),auxillarygas
pressure (2 units), capillary temperature [370 ◦C and the capillary
offset at 35 V. HPLC kinetex columns were used (100 mm ×
3 mm, 2.6u C18(2)-HST; Phenomenex]. The run method was
isocratic 10% (0.1% formic acid in water) and 90% methanol.
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Figure 4 Acute effects of PI3K inhibitors on insulin levels during the GTT
The indicated PI3K inhibitors were administered intraperitoneally (10mg/kg of body mass) and a GTT was performed as described in Figure 3. Insulin levels were measured in blood samples
taken at the indicated time as described in the Experimental section. Results are means+ −S.E.M. (n6). Statistical signiﬁcance was determined by repeated measures ANOVA (**P <0.01 and
***P <0.001 compared with the vehicle control animals).
The ﬂow rate was 0.2 ml/min. Retention times were 2.64 min
(PI-103),2.76 min(TGX221)and2.35 min(IC87114).Unknown
concentrations were determined from the standard curve and
internal standard.
RESULTS
Drug pharmacokinetics
We have reported previously pharamacokinetic data for BEZ235
and A66 [28]. In the present paper we report pharmacokinetic
data for PI-103, TGX221 and IC87114 following oral or
intraperitonealinjection(SupplementaryFigureS1athttp://www.
BiochemJ.org/bj/442/bj4420161add.htm). These studies estab-
lished that an intraperitoneal dose of 10 mg/kg of body mass gave
suitable blood concentrations of drug for short-term metabolic
studies.
Effect of inhibitors on whole-body glucose metabolism
The results of the present study show that the pan-PI3K/mTOR
inhibitors PI-103 and BEZ235, and the pan-PI3K inhibitor
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Figure 5 Effect of PI3K inhibitors on oxygen consumption, BMR, food consumption and water intake
Animals were injected with the indicated PI3K inhibitors intraperitoneally (10mg/kg of body mass) and were observed for 24h following injection in a CLAMS metabolic cage as described in the
Experimental section. The results are shown for oxygen consumption (A), BMR (B), food intake during the day (C), food intake during the night (D), water intake during the day (E) and water intake
during the night (F). Results are means+ −S.E.M. (n6). Statistical signiﬁcance was determined by one-way ANOVA and Dunnett’s multiple comparison test (*P <0.05 and **P <0.01 compared
with the vehicle control animals).
ZSTK474 severely impaired whole-body glucose metabolism in
mice (Figures 1–4). The ﬁnding that the drugs induced severe
impairments in insulin tolerance (Figure 1) suggests they are
causing insulin resistance at the level of one or all of the major
insulin target tissues, i.e. muscle, liver or fat. The ﬁnding that
they all increased production of glucose from pyruvate in a
PTT (Figure 2) indicates that gluconeogenesis is increased and
provides evidence that insulin action in the liver is impaired.
Further evidence that the drugs induce insulin resistance comes
from the GTT results which show that all three of these pan-PI3K
inhibitors induced signiﬁcant impairments in the ability of the
mice to dispose of a glucose load (Figure 3). Of the isoform-
selective class-IA PI3K inhibitors, PIK75 and A66 induced
signiﬁcant impairments in the ITT and GTT, and an increase in
glucose production during a PTT (Figures 1–3), with TGX221
and IC87114 having only minor effects. AS252424 caused a
signiﬁcantincreaseinhepaticglucoseproduction(Figure2H)and
a trend towards an impairment in insulin tolerance (Figure 1H).
AS252424 was originally described as a p110γ-selective
inhibitor, but the ﬁndings above lead us to re-evaluate this and we
ﬁnd that it inhibits p110γ with an IC50 value of 17 nM (compared
with 30 nM reported in [31]) and p110α with an IC50 value of
80 nM (compared with 935 nM reported in [31]). Therefore in
vivo this inhibitor is likely to be cross-reacting with p110α.
One possible explanation for defects in glucose metabolism
could be an inhibitory effect on insulin release as such effects
have been reported previously in vitro [37]. However, insulin
levelsdidnotdecreaseinthedrug-treatedanimalsduringtheGTT
(Figure 4). In fact insulin levels rose in the case of the pan-PI3K
inhibitors and PIK75 and A66, in line with the impaired glucose
toleranceaswouldbeexpectedinaninsulin-resistantstate.There-
fore, although a small effect on insulin release can not be ruled
out, the drugs certainly don’t completely block insulin release.
We were also interested to investigate whether acute
administration of these PI3K inhibitors might affect energy
expenditure and so we performed metabolic cage studies.
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Figure 6 Effects of PI3K inhibitors on movement
The indicated PI3K inhibitors were administered intraperitoneally (10mg/kg of body mass) and measurements of animal movement were made over a 24h period in metabolic cages as described in
the Experimental section. The results are shown for the total X-counts during the day (A), total X-counts during the night (B), total Z-counts during the day (C) and total Z-counts during the night
(D). Results are means+ −S.E.M. (n6). Statistical signiﬁcance was determined by one-way ANOVA and Dunnett’s multiple comparison test (*P <0.05, **P <0.01 and ***P <0.001 compared
with the vehicle control animals).
These studies did not ﬁnd any changes in BMR or oxygen
consumption (Figure 5). Neither were there major changes
in water consumption. However, BEZ235 induced signiﬁcant
reductions in food intake in both the light and dark cycle, whereas
PI-103 and PIK75 caused signiﬁcant decreases in food intake
during the light cycle (Figure 5).
During the metabolic cage studies, data were also obtained on
animal movement. Surprisingly this showed that a number of the
inhibitors induced a reduction in movement and that this was an
acute effect of the drugs (Figure 6). The reduction in movement
was mainly due to a reduction in Z-movement (i.e. up–down
movement) (Figure 6). It is notable that the pan-PI3K inhibitors
PI-103 and BEZ235, and both of the p110α-selective inhibitors,
were the inhibitors that caused the largest effects.
DISCUSSION
The present study shows that the pan-PI3K/mTOR inhibitors PI-
103 and BEZ235 have dramatic effects on whole-body glucose
metabolism. This extends the ﬁndings of Knight et al. [26] who
demonstrated that PI-103 induced impairments in insulin toler-
ance. The present study also shows that PIK75 caused a serious
impairment of glucose metabolism in mice. This also extends the
ﬁndingsofKnightetal.[26]whoonlylookedatinsulintolerance.
They concluded that this was evidence for an important role for
p110α in regulating glucose metabolism in vivo. However, PIK75
is a suboptimal inhibitor to use for such studies as it has a number
of off-target effects, including inhibition of p110γ and a number
of protein kinases. However, the effects of PI-103 and BEZ235
are most likely not to be due to inhibition of mTOR as ZSTK474,
which inhibits class-I PI3K isoforms, but not mTOR, has very
similareffects.Furthermore,itisunlikelytobeduetoinhibitionof
class-II PI3Ks as PI-103 and PIK75 do not inhibit these isoforms
[26]. Using a number of different inhibitors with different proﬁles
against protein kinases also guards against the possibility that the
effectofthedrugsmightbeduetooff-target effects.Furthermore,
we ﬁnd PI-103, BEZ235 and ZSTK474 (Supplementary Table S1
at http://www.BiochemJ.org/bj/442/bj4420161add.htm) and A66
[28] have very low levels of off-target activity.
The present study is the ﬁrst to examine the effect of a
selective p110α inhibitor (A66) on glucose metabolism in vivo.
We ﬁnd that A66 impairs all measures of in vivo insulin
action, almost to the same level as the pan-PI3K inhibitors.
This provides strong pharmacological evidence that p110α is
the most important isoform in the pathways acutely regulating
glucose metabolism, and that functional redundancy between
PI3Kisoformsisunlikelytobeamajorfeatureofmajorpathways
regulating glucose metabolism in vivo [32]. The effects of A66
on glucose metabolism are a phenocopy of mice heterozygous for
global expression of a kinase-dead form of p110α [18]. However,
even though A66 is inhibiting p110α globally, the results of
the present study are also remarkably similar to those seen in
mice in which the Pik3ca gene had been deleted either acutely or
chronicallyonlyinliver[19].TakentogetherwithourPTTresults
this suggests that a major site of action of the p110α in regulating
the effects of insulin on glucose metabolism is in liver.
An area where our studies do not correlate with genetic studies
is with regard to p110β inhibition. Two previous studies have
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analysed the role of p110β in glucose metabolism using genetic
models.OneofthesewasaKImodel,whichcreatedakinase-dead
form of p110β [21], whereas the other ablated p110β speciﬁcally
inliver[20].Bothofthesemodelsshowedimpairmentsofglucose
tolerance and insulin tolerance, as well increased hepatic
glucose output, which is a similar phenotype to that seen in our
studies with pan-PI3K inhibitors. However, we only see minor
changes in glucose metabolism in animals treated with TGX221
and these do not achieve statistical signiﬁcance. This is supported
by the studies of Knight et al. [26] who found that the p110β
inhibitor TGX115 did not affect insulin tolerance in mice. One
explanation could be that the defects in glucose metabolism
seen in the genetic studies [20] may be caused by long-term
effects of the loss of p110β function, which are not seen with
acute inhibition of the catalytic activity of the enzyme. Another
explanation would be that our results support a non-catalytic role
for the p110β in pathways controlling metabolism in the liver, as
has previously been suggested [20].
The ﬁnding of the present study that some of the drugs induce
a small reduction in food intake differs from previous studies
in genetic mouse models [18,38] and our own studies in which
isoform selective PI3K inhibitors were directly injected into the
brain [39]. Those studies have indicated that a reduction in p110α
and p110β activity in the brain actually leads to increased food
intake rather than a decrease. It is not clear why the drugs in the
present study did not induce a similar effect, but it may be related
to the fact that they were administered peripherally and so they
may not be crossing the blood–brain barrier to a sufﬁcient extent
to achieve such effects. Also, the reduced food intake does not
necessarilymeanareducedappetiteasthereductioninmovement
may be preventing the animals from eating.
The reduction in movement seen in mice treated with pan-
PI3K inhibitors or the p110α-selective inhibitors is interesting. A
s i m i l a rr e d u c t i o ni nm o v e m e n tw a so b s e r v e di nm i c ei nw h i c ht h e
p110α gene had been deleted in the liver [19]. One interpretation
of this would be that p110α plays some previously unsuspected
role in regulating movement, but it is also possible that it is a side
effect of the off-target actions of the drugs. Further studies will
be required to resolve this issue.
In summary, the results of the present study provide strong
pharmacological evidence to support the contention that p110α
activity is necessary for the pathways regulating glucose
metabolism in vivo. The results also show that acute dosing
with pan-PI3K and p110α inhibitors have effects on food intake
and animal movement, indicating that the these effects should be
monitored in human clinical trials using PI3K inhibitors.
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Figure S1 Levels of drug in mouse blood after administration
I.P, intraperitoneal.
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Table S1 Effect of compounds on enzyme activities
Resultsarethepercentageenzymeactivityremainingaftertreatmentwith10μMofthedrug.EnzymeassayswereperformedbytheNationalCentreforProteinKinaseProﬁling,UniversityofDundee,
Dundee, U.K. Results are means of duplicate determinations. AMPK, AMP-activated protein kinase; ASK1, apoptosis signal regulating kinase 1; BRSK, BR serine/threonine kinase; BTK, Bruton
agammaglobulinemia tyrosine kinase; CAMK, calcium/calmodulin-dependent protein kinase; CAMKK, CAMK kinase; CHK, checkpoint kinase; CDK, cyclin-dependent kinase; CK, casein kinase;
CLK2,CDC-like kinase 2;CSK, c-Src tyrosine kinase;DAPK1, death-associated protein kinase 1; DYRK, dual-speciﬁcitytyrosine-(Y)-phosphorylation-regulatedkinase; EF2K,eukaryoticelongation
factor-2 kinase; EPH, Ephrin type receptor; ERK, extracellular-signal-regulated kinase; FGF, ﬁbroblast growth factor receptor 1; GCK, glucokinase (hexokinase 4); GSK3, glycogen synthase kinase
3; HIPK1, homeodomain interacting protein kinase 1; IGF-1R, insulin-like growth factor 1 receptor; IKK, Inhibitor of nuclear factor κ-B kinase; IR, insulin receptor; IRR, insulin receptor-related
receptor; IRAK4, interleukin-1 receptor-associated kinase 4; JAK2, Janus kinase 2; JNK, c-Jun N-terminal kinase; Lck, lymphocyte-speciﬁc protein tyrosine kinase; LKB1, liver kinase B1; MAPK,
mitogen-activated protein kinase; MKK, MKK kinase; MNK, MAPK-interacting serine/threonine kinase; MAPKAP, MAPK-associated protein; MARK, microtubule afﬁnity-regulating kinase; MEKK1,
MAPK/ERK kinase kinase 1; MELK, maternal embryonic leucine zipper kinase; MINK1, misshapen-like kinase 1; MLK, mixed lineage kinase; MSK1, mitogen- and stress-activated protein kinase
1; MST, mammalian STE20-like protein kinase; NEK, NIMA (never in mitosis gene a)-related kinase; PAK, p21 protein (Cdc42/Rac)-activated kinase; PKB, protein kinase B; PDK1, pyruvate
dehydrogenase kinase 1; PHK, phosphorylase kinase; PKA, protein kinase A; PKC, protein kinase B; PKD, protein kinase D; PLK1, polo-like kinase 1; PRAK, p38-regulated/activated protein kinase;
PRK2, protein-kinase C-related kinase 2; RIPK2, receptor-interacting serine-threonine kinase 2; ROCK2, Rho-associated coiled-coil-containing protein kinase 2; RSK, ribosomal S6 kinase; SGK1,
serum/glucocorticoid regulated kinase 1; S6K1, S6 kinase 1; SmMLCK, smooth muscle myosin light chain kinase; Src, v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homologue; SRPK1,
SRSF protein kinase 1; SYK, spleen tyrosine kinase; TAK1, transforming growth factor-β-activated kinase 1; TAO1, TAO kinase 1; TBK1, TANK [TRAF (tumour-necrosis-factor-receptor-associated
factor)-associated nuclear factor κB activator]-binding kinase 1; TRKa, TRK1-transforming tyrosine kinase protein; TTK, TTK protein kinase; YES1, v-yes-1 Yamaguchi sarcoma viral oncogene
homologue 1; VEGFR, vascular endothelial growth factor receptor.
Enzyme PI-103 (10μM) AS252424 (10μM) BEZ235 (10μM) ZSTK474 (10μM)
MKK1 105 70 116 83
MKK2 115 77 86 95
MKK6 107 99 93 83
ERK1 112 85 106 106
ERK2 106 104 114 105
JNK1 102 99 105 93
JNK2 100 85 89 87
JNK3 101 90 93 88
p38α MAPK 109 86 111 89
p38β MAPK 100 74 96 95
p38γ MAPK 76 65 101 92
p38δ MAPK 84 38 100 107
ERK8 87 10 94 92
RSK1 101 88 97 95
RSK2 96 40 81 83
PDK1 107 97 98 92
PKBα 78 97 126 123
PKBβ 114 40 106 84
SGK1 92 59 98 98
S6K1 90 43 109 98
PKA 100 66 82 76
ROCK2 91 70 84 85
PRK2 71 88 74 82
PKCα 93 102 87 86
PKCζ 98 96 123 87
PKD1 120 55 107 96
MSK1 105 54 102 89
MNK1 97 48 101 96
MNK2 90 62 94 101
MAPKAP-K2 90 80 99 91
MAPKAP-K3 100 63 110 97
PRAK 77 64 93 82
CAMKKb 114 51 61 87
CAMK1 99 46 100 114
SmMLCK 48 37 109 91
PHK 84 61 95 94
DAPK1 30 8 107 75
CHK1 115 87 146 90
CHK2 85 53 80 88
GSK3b 48 10 76 79
CDK2-Cyclin A 94 89 74 77
PLK1 93 90 95 75
Aurora A 92 95 104 99
Aurora B 95 71 101 94
LKB1 62 52 105 103
AMPK 99 39 99 92
MARK1 91 88 97 106
MARK2 107 90 86 87
MARK3 88 67 100 94
MARK4 108 63 81 89
BRSK1 109 56 85 161
BRSK2 99 44 89 88
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Table S1 Continued
Enzyme PI-103 (10μM) AS-252424 (10μM) BEZ235 (10μM) ZSTK474 (10μM)
MELK 104 91 35 91
NUAK1 98 73 44 90
CK1 100 85 96 76
CK2 102 25 79 54
DYRK1A 59 3 93 78
DYRK2 83 20 79 93
DYRK3 64 18 56 87
NEK2a 86 136 145 106
NEK6 87 94 95 83
IKKb 74 73 92 94
IKKe 85 40 86 84
TBK1 91 70 107 102
PIM1 72 7 92 97
PIM2 90 7 94 92
PIM3 41 7 87 76
SRPK1 116 39 106 92
EF2K 99 91 110 96
HIPK1 63 29 89 100
HIPK2 18 3 101 63
HIPK3 82 23 102 98
CLK2 25 16 53 85
PAK2 106 89 87 100
PAK4 70 65 87 92
PAK5 112 49 90 84
PAK6 108 71 105 93
MST2 115 60 89 92
MST4 114 45 100 88
GCK 91 53 12 104
MINK1 116 24 75 102
MEKK1 97 56 67 92
MLK1 65 53 67 86
MLK3 57 32 62 97
TAO1 84 18 81 93
ASK1 101 110 106 90
TAK1 79 48 67 97
IRAK4 119 114 78 102
RIPK2 72 19 28 89
TTK 66 56 91 88
Src 99 96 121 104
Lck 85 110 54 89
CSK 101 100 100 84
YES1 92 36 69 72
BTK 82 45 20 98
JAK2 93 60 24 79
SYK 69 55 72 85
EPH-A2 113 51 110 106
EPH-A4 103 74 105 87
EPH-B1 131 94 133 96
EPH-B2 105 100 77 106
EPH-B3 127 52 117 113
EPH-B4 86 89 99 105
FGF-R1 118 42 106 102
HER4 114 68 117 103
IGF-1R 54 75 72 87
IR 80 94 99 104
IRR 89 36 80 88
TrkA 93 79 59 83
VEGFR 92 22 80 87
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